Nexplanon 68 MG implants
Ended Awarded
- Contract number
- SPE2DR26FRRE1
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $12,787
Award facts
- Contract value 100% obligated
- $12,786.66 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $12,786.66 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for 68 mg Nexplanon implants. The award, made on November 20, 2025, with an ultimate completion date of December 12, 2025, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to establish multiple regional prime vendor contractors supporting Department of Defense pharmaceutical supply needs.
The PPV-G GEN V contract, awarded to DMS Pharmaceutical Group on November 13, 2025, carries a ceiling value of $499,999,999 and extends through December 31, 2036, with a 30-month base period and three 30-month option periods. This strategic contract positions DMS Pharmaceutical Group to serve as a critical supplier of branded and generic prescription medications, biologics, vaccines, and medical consumables to military healthcare facilities worldwide. The contractor's established performance across numerous delivery orders—spanning specialty pharmaceuticals, oncology treatments, immunosuppressants, and routine medications—demonstrates its capability to fulfill the diverse pharmaceutical requirements of the federal military medical system without identified subcontractor relationships.
Quick answers
Who was awarded contract SPE2DR26FRRE1?
SPE2DR26FRRE1 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on November 20, 2025.
How much is contract SPE2DR26FRRE1 worth?
The government has obligated $12,787 on SPE2DR26FRRE1.
Is contract SPE2DR26FRRE1 an order under another contract?
Yes. SPE2DR26FRRE1 is a delivery order under SPE2DR25D9238, an indefinite delivery contract.
Was contract SPE2DR26FRRE1 competed?
The extent of competition for SPE2DR26FRRE1 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award